CD274 and neoplasm: Immune checkpoint blockades (ICBs), represented by monoclonal antibodies to block the PD-1/PD-L1 pathway, exhibit remarkable anti-cancer effect by activating T-cell immune responses within the tumor microenvironment (TME) 1, 2.